Clinical Trial Update: Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether adding selumetinib to radioactive iodine improves outcomes in patients with recurrent or metastatic thyroid cancer; results hav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Carcinoma
• Papillary Thyroid Carcinoma
• Poorly Differentiated Thyroid Carcinoma
• Thyroid Cancer

Drugs mentioned

• Iodine-131 (Iodine-131)
• Selumetinib (selumetinib)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-08-03